What Дельтаран Treats: Main Uses and Benefits

The drug may be part of symptomatic management in therapeutic domains involving symptoms that create noticeable physiological strain.

The medication is commonly used to help with conditions characterized by periods of heightened symptoms of psycho-emotional tension, asthenia, and chronic fatigue. It is also applied across domains where additional symptomatic support is needed in contexts involving heightened systemic burden following systemic or cerebral challenges.

The medication may be used to provide support that helps ease the overall symptom burden and assists with maintaining functional stability when symptoms interfere with routine activities. It is considered relevant in contexts involving heightened systemic burden. The supportive approach assists with maintaining functional stability when symptoms interfere with routine activities.

---

Quick Fact: Symptomatic Support

Focus	Context	Benefit
Symptom Cluster	Psycho-emotional tension, chronic fatigue, asthenia.	Contributes to improved comfort during symptomatic periods.
Condition Type	Conditions presenting with systemic or localized discomfort.	Provides supportive relief when symptoms interfere with routine activities.

The eligibility for using Дельтаран (Tryptophanyl-alanyl-glycyl-glycyl-aspartyl-alanyl-seryl-glycyl-glutamic acid) is strictly defined by regulatory documents, which outline absolute exclusions based on age, reproductive status, and specific neurological conditions.

---

Populations Explicitly Contraindicated

The medicine is formally contraindicated and must not be used in the following populations:

• Pediatric Use: The drug is prohibited in children and adolescents (under 18 years of age).
• Reproductive Status: Use is contraindicated during both pregnancy and lactation (breastfeeding).
• Hypersensitivity: Individuals with a known hypersensitivity to the active substance or any excipients.
• Neurological Conditions: Patients with a history of convulsive conditions (epilepsy) or a demonstrated tendency toward seizures are contraindicated.
• Infections: Contraindicated during the acute phase of severe infectious diseases of the nervous system.

---

Age and Condition Eligibility

The medicine is restricted to the adult population who do not have any of the absolute contraindications. Official regulatory documents do not specify eligibility restrictions based on renal or hepatic impairment.

The active ingredient in Дельтаран, Tryptophanyl-alanyl-glycyl-glycyl-aspartyl-alanyl-seryl-glycyl-glutamic acid, is a short-chain peptide. The official regulatory interaction profile for this substance is notably simplified, reflecting its rapid metabolism in the body.

Interaction Scope and Constraints

The prescribing information documented by government health authorities indicates that no specific drug-drug interactions, pharmacokinetic effects, or pharmacodynamic effects have been formally identified as clinically significant.

Consequently, the regulatory labeling does not contain an explicit list of contraindicated combinations or specific medicinal products that must be avoided. No formal statements regarding the active substance acting as a substrate, inhibitor, or inducer of major metabolic enzymes (such as Cytochrome P450, or CYP) or drug transporters are documented.

Regulatory Interaction Status

Due to the absence of documented interactions, the official regulatory profile confirms that no mandatory timing separation or dose-spacing requirements are imposed for co-administration with other treatments. Furthermore, official labeling contains no specific constraints or warnings related to co-use with food, alcohol, or herbal products in the interaction section. No population-specific adjustments related to interaction risks, such as those for patients with hepatic impairment, are formally noted. The overall structure of the product’s interaction data is characterized by the absence of specific, documented interacting entities.

How Дельтаран Works: The Mechanism of Cellular Stabilization

Modulating Neuronal Excitation and Inhibition

The peptide acts as a regulator by influencing the core balance between the brain's major signaling systems: Glutamate (excitatory) and GABA (inhibitory). Its mechanism centers on attenuating excessive glutamatergic signaling, which is a primary driver of neuronal damage known as excitotoxicity. This action stabilizes the balance and attenuates overstimulation, which contributes to the functional integrity of nerve cells.

---

Modulation of Intrinsic Cellular Protection

The action extends beyond neurotransmitters to the cellular defense mechanisms themselves. The drug promotes the upregulation of endogenous antioxidant systems, such as enzymes like Superoxide Dismutase (SOD). This induction increases the cell's capacity to neutralize harmful reactive oxygen species (ROS), thereby mitigating oxidative stress and maintaining metabolic stability when the cell is under acute or chronic strain.

---

Physiological Outcome: Modulation of Adaptive Capacity

The combination of reducing excessive excitability and modulating internal antioxidant defenses constitutes the core of its neuroprotective mechanism. This dual action allows neurons to maintain energy function and contribute to cellular viability, which translates physiologically into an increased tolerance for metabolic challenges, such as hypoxia, thereby influencing the overall adaptive capacity of the nervous system.

Administration Guidelines for Дельтаран

The usage of Дельтаран (Tryptophanyl-alanyl-glycyl-glycyl-aspartyl-alanyl-seryl-glycyl-glutamic acid) involves specific parameters regarding the route, dosage, and course structure.

---

Route, Form, and Preparation

Дельтаран is supplied as a lyophilisate (a powder for reconstitution) containing 0.3 mg of the active nonapeptide per ampoule. Its route is intranasal administration, not standard injection. The powder is dissolved immediately prior to use in 0.5 mL of boiled water at room temperature. The resulting solution is intended for immediate, complete use and is not for storage.

---

Dosage and Treatment Course

The standard adult dosing regimen involves a total daily dose typically ranging from 1 to 3 ampoules (0.3 mg to 0.9 mg) of the active substance. This dose is generally administered once daily as part of a structured treatment cycle. The treatment is used over a defined course lasting between 5 and 15 days. Should a subsequent course be required, a defined interval of 4 to 8 weeks is observed before readministration.

---

Specific Usage Constraints

Usage involves specific restrictions regarding certain populations. The medicine is not for use in individuals under 18 years of age or during pregnancy and breastfeeding. Furthermore, if the nasal passages are inflamed (e.g., due to acute rhinitis), administration is performed after a nasal wash or the use of a decongestant medication to facilitate proper absorption.

Research Evidence / Overview of Studies for Дельтаран

This overview describes the types of clinical investigations conducted for Дельтаран and the structure of the existing evidence base, adhering strictly to official and peer-reviewed scientific information. This summary does not provide medical advice, dosing instructions, or information on safety or side effects.

---

Evidence for Symptomatic Relief in Contexts of Psycho-Emotional Strain

Research was studied for its use in specific symptom clusters. The types of studies conducted include clinical and observational studies, often local in scope, which explore how symptoms change over time when the medication is evaluated in these settings. This research explored outcomes related to systemic or functional imbalance, specifically psycho-emotional tension, asthenia, and chronic fatigue. These studies also monitored patient-reported outcomes describing perceived discomfort and the overall functioning or activity level of the participants.

Findings from these studies describe patterns observed in the research cohorts, generally reporting how symptoms evolved over the short-term study period. However, the evidence level is limited because the research base is not widely supported by large, pivotal, multi-center studies or systematic reviews indexed by major international regulatory agencies.

---

Evidence for Neuroprotective and Cellular Resilience Research

Research has explored the agent's potential role beyond symptomatic relief, specifically examining anti-stress and neuroprotective effects at a foundational, biological level. The evidence base here is primarily built on experimental studies and smaller-scale clinical studies. These investigations monitored outcomes linked to physiological strain or stress, such as changes in cellular resilience and regional blood supply (e.g., cerebral).

---

Long-Term Studies, Follow-Up Data, and Uncertainties

Research has focused on short-term symptom changes and immediate physiological responses. The data available primarily reflects early-phase mechanistic findings, and the translation into consistent, large-scale, long-term clinical trial evidence is not yet clear.

Consequently, there is limited information for long-term outcomes or data that would help contextualize how durable any observed patterns are over many months or years. The overall certainty of the evidence base remains low, reflecting limitations like modest sample sizes and insufficient data for specific patient groups, such as children or older adults.

Common questions about Дельтаран (FAQ)

Q: What is the role of Дельтаран in supporting the central nervous system?

Official documents describe the drug's mechanism of action as regulating the critical balance between the brain's major signaling systems, known as Glutamate and GABA. It works to attenuate excessive overstimulation, a process known as excitotoxicity, which contributes to maintaining the functional integrity of nerve cells. This action is described as contributing to the cell's natural resilience to stress and metabolic challenges.

Q: What is Delta-sleep inducing peptide (DSIP) and what does it do in the body?

The core component of this medicine is a synthetic neuropeptide (a small, protein-like molecule). This substance is a synthetic analogue of naturally occurring regulatory substances in the body. It is characterized in scientific literature for its role as a stress protector and endogenous regulator.

Q: Can older adults or geriatric patients use Дельтаран without special precautions?

The medicine is restricted for use in the adult population, and regulatory documents do not specify special precautions for older adults who do not have absolute contraindications. Official research summaries acknowledge that there is limited certainty and insufficient data regarding the long-term outcomes for specific patient groups, including seniors.

Q: What does official data say about using Дельтаран in people with pre-existing low blood pressure?

Regulatory safety documents state that changes in blood pressure are documented as an uncommon adverse reaction that may occur during treatment. Regulatory information clarifies that pre-existing low blood pressure is not formally listed as a contraindication or exclusion criterion in the regulatory documentation.

Q: Is it normal to feel a change in energy levels after starting Дельтаран?

Studies indicate the medicine has been investigated for outcomes related to systemic imbalance, including asthenia (lack of strength or energy) and chronic fatigue. Conversely, official safety documents list insomnia (difficulty sleeping) and anxiety as uncommon adverse reactions that have been reported.

Q: Is the anti-ischemic effect of Дельтаран a primary or secondary action of the drug?

The primary described mechanism is its neuroprotective dual action, which involves reducing excessive excitability and modulating internal antioxidant defenses. This foundational action is described as contributing to the maintenance of neuronal energy function and influencing tolerance to metabolic challenges, which includes the effect of improving regional blood supply (anti-ischemic effect) under strain.

Q: Is there any information about Дельтаран affecting daily activities like driving?

The official safety documentation lists dizziness as a common side effect of the medicine. Official guidance related to central nervous system effects typically advises caution when engaging in daily activities that require complete concentration or mental alertness.

Q: How does the body break down and eliminate Дельтаран after it is used?

Regulatory information reflects that the active substance in the drug undergoes a rapid metabolism in the body after administration. This rapid breakdown contributes to the drug's notably simplified regulatory interaction profile, as no specific pharmacokinetic interactions are formally identified.

How to Store and Dispose of Дельтаран

All storage and disposal requirements for Дельтаран (Deltaran) must strictly follow the conditions specified in the official regulatory labeling.

---

Mandatory Storage Conditions

Condition	Requirement
Temperature	Store in a refrigerator at 2, C to 8, C (36, F to 46, F).
Prohibition	Do not freeze the medicinal product.
Protection	Store in the original outer carton to protect it from light.

Stability and Handling

Once the powder for injection is reconstituted, the solution has a defined, time-limited stability period (e.g., 8 hours) when stored at room temperature, not exceeding 25, C. Any unused portion of the reconstituted solution must be discarded after this period.

Disposal and Safety

Unused or expired product and waste material must be disposed of in accordance with local regulations for pharmaceutical waste; it must not be discarded into household waste or wastewater. The medicine must also be kept out of the sight and reach of children.